Topical JAK inhibitor Provides Sustained Control of HS

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Ruxolitinib cream applied on an as-needed basis provided sustained clearance of hidradenitis suppurativa nodules during the open-label extension of a phase 2 trial.
Medscape Medical News